Antiemetic drug revenues to reach $4.6bn in 2018, a new analysis predicts

Monday 30 June 2014, Amsterdam

Patients worldwide have increasing needs for treatment of nausea and vomiting, especially as part of cancer therapy. A new report, now available on ASDReports, forecasts the world market for antiemetic drugs will reach $4.6 billion in 2018, rising further to 2024. That sales prediction and others appear in Antiemetic Drugs: World Industry and Market Analysis 2014-2024, published in May 2014.

Hemant Mistry, a pharmaceutical industry analyst, said: “Our analysis predicts the overall market for antiemetic drugs will expand from 2014 to 2024. This will correlate with the global rise in cancer levels - cancer treatment is the leading cause of nausea and vomiting. We predict as patient numbers of chemotherapy and radiation treatment grow, prescriptions of antiemetic drugs will rise. Producers of those drugs will benefit, as will patients.

“Also, to encourage treatment compliance, drug companies are developing antiemetic therapies with novel delivery methods. The use of transdermal granisetron patches, for example, offers patients greater convenience and a reduction in pill counts.

“And an overhaul in the design of antiemetic drug trials needs to be introduced. This would help predict which patients are likely to suffer from emesis after a particular chemotherapy regimen. This information would allow for a better assessment of the safety and efficacy of new treatments. Without addressing this, delays in product approval and issues in post-market surveillance are inevitable.”

The new report shows revenue forecasts to 2024 at overall world, drug class, product and national level. It forecasts global revenues for four antiemetic drug classes:

• 5-HT3 antagonists
• Cannabinoids
• Dopamine antagonists
• Other agents (grouped).

That study also explores research and development (R&D), shows qualitative analyses (SWOT and STEP) and gives an interview with a company in the industry.

The investigation also discusses trends and predicts overall revenues of anti-vomiting medicines to 2024 in leading national markets. It analyses the US, Japan, Germany, France, the UK, Italy, Spain (EU5 countries), China, India, Russia and Brazil (BRIC nations).

Antiemetic Drugs: World Industry and Market Analysis 2014-2024 adds to the range of reports on pharmaceutical industries and markets.